Medivation Company Profile (NASDAQ:MDVN)

About Medivation

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MDVN
  • CUSIP: 58501N10
Key Metrics:
  • Previous Close: $80.27
  • 50 Day Moving Average: $63.91
  • 200 Day Moving Average: $52.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 37.16
  • P/E Growth: 1.68
  • Market Cap: $13.32B
  • Outstanding Shares: 165,928,000
  • Beta: 0.87
Additional Links:
Companies Related to Medivation:

Analyst Ratings

Consensus Ratings for Medivation (NASDAQ:MDVN) (?)
Ratings Breakdown: 1 Sell Rating, 15 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: $77.84 (3.02% downside)

Analysts' Ratings History for Medivation (NASDAQ:MDVN)
DateFirmActionRatingPrice TargetDetails
8/22/2016Maxim GroupSet Price TargetBuy$76.00View Rating Details
8/23/2016Canaccord GenuityReiterated RatingBuy$70.00 -> $82.00View Rating Details
8/23/2016BMO Capital MarketsBoost Price TargetMarket Perform$67.16 -> $81.50View Rating Details
8/23/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$81.50View Rating Details
8/23/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
8/22/2016SunTrust Banks Inc.DowngradeBuy -> NeutralView Rating Details
8/22/2016Citigroup Inc.DowngradeBuy -> Neutral$73.00 -> $81.50View Rating Details
8/22/2016WedbushDowngradeOutperform -> Neutral$81.50View Rating Details
8/22/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/22/2016Barclays PLCDowngradeOverweight -> Equal Weight$70.00 -> $81.00View Rating Details
8/10/2016Leerink SwannSet Price TargetHold$64.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingHold$56.00 -> $60.00View Rating Details
8/10/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
5/7/2016Royal Bank Of CanadaReiterated RatingSector Perform$40.00 -> $70.00View Rating Details
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00View Rating Details
5/1/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$44.00View Rating Details
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details
4/4/2016BTIG ResearchReiterated RatingHoldView Rating Details
2/19/2016Bank of America Corp.Initiated CoverageBuy$45.00View Rating Details
1/31/2016William BlairReiterated RatingOutperform$83.00View Rating Details
9/15/2015NomuraInitiated CoverageBuy$140.00View Rating Details
3/25/2015JPMorgan Chase & Co.Boost Price TargetOverweight$130.00 -> $148.00View Rating Details
9/15/2014AegisReiterated RatingBuyView Rating Details
9/12/2014Chardan CapitalBoost Price TargetBuy$100.00 -> $122.00View Rating Details
9/9/2014Sanford C. BernsteinUpgradeMarket Perform -> Outperform$118.00View Rating Details
(Data available from 8/23/2014 forward)


Earnings History for Medivation (NASDAQ:MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.27$0.29$214.52 million$206.00 millionViewN/AView Earnings Details
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details
2/25/2016Q415$0.25$0.29$373.85 million$377.74 millionViewListenView Earnings Details
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details
11/12/2013Q313($0.26)($0.18)$60.13 million$108.50 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details
8/9/2012$0.23($0.15)ViewN/AView Earnings Details
5/8/2012$1.19$0.01ViewN/AView Earnings Details
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medivation (NASDAQ:MDVN)
Current Year EPS Consensus Estimate: $1.28 EPS
Next Year EPS Consensus Estimate: $2.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20165$0.18$0.26$0.21
Q3 20162$0.24$0.25$0.25
Q4 20162$0.31$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medivation (NASDAQ:MDVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Medivation (NASDAQ:MDVN)
DateHeadline logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. to Pfizer Inc. is Fair to Shareholders (NASDAQ:MDVN) - August 23 at 6:20 PM
News IconMedivation Inc (MDVN) Soars On Pfizer Bid - ValueWalk (NASDAQ:MDVN) - August 22 at 6:06 PM logoMarkets focus on big mergers as global stocks are quiet (NASDAQ:MDVN) - August 22 at 6:06 PM logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information (NASDAQ:MDVN) - August 22 at 6:06 PM logoWhy no other drug maker was able to close the Medivation deal (NASDAQ:MDVN) - August 22 at 5:56 PM logoWhy Intersil Corp (ISIL), Medivation Inc (MDVN) and United States Steel Corporation (X) Are 3 of Today’s Best Stocks (NASDAQ:MDVN) - August 22 at 5:15 PM logoBiotechs Rise on Bet Medivation Losers Will Look to Next Deal - Bloomberg (NASDAQ:MDVN) - August 22 at 2:48 PM logoPfizer to Acquire Medivation (NASDAQ:MDVN) - August 22 at 10:43 AM
News IconIn possible $14 billion ending, Medivation (NASDAQ: MDVN) goes back to early days with Pfizer (NYSE: PFE) (NASDAQ:MDVN) - August 22 at 10:43 AM
News IconPfizer to Acquire Medivation in Deal Worth $14 Billion -- 4th Update (NASDAQ:MDVN) - August 22 at 10:43 AM
News IconPfizer buys Medivation, the Crown Jewel in cancer therapy (NASDAQ:MDVN) - August 22 at 10:43 AM logoMedivation Inc (MDVN) Stock Skyrockets on $14 Billion Pfizer Inc. (PFE) Deal (NASDAQ:MDVN) - August 22 at 10:43 AM
News IconMedivation Inc. (MDVN) to Be Acquired by Pfizer for $14B (NASDAQ:MDVN) - August 22 at 10:43 AM logo[$$] Pfizer Adds Key Drug for Cancer in $14 Billion Deal (NASDAQ:MDVN) - August 22 at 10:43 AM logoWall Street opens lower as Pfizer seals Medivation deal (NASDAQ:MDVN) - August 22 at 10:43 AM logoPfizer buys Medivation $14 billion cash (NASDAQ:MDVN) - August 22 at 10:43 AM logoPfizer Won the Bidding War for Medivation But Is It Really a Win? (NASDAQ:MDVN) - August 22 at 10:43 AM logoNasdaq Turns Up; Medivation, Syngenta, Intersil Soar On Merger News (NASDAQ:MDVN) - August 22 at 10:43 AM logoMore Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion (NASDAQ:MDVN) - August 22 at 10:43 AM logoPfizer-Medivation Deal Headlines Busy Merger Monday (NASDAQ:MDVN) - August 22 at 10:43 AM logoPfizer just spent $14 billion on a company with just one approved drug — here's why that's a game-changer (NASDAQ:MDVN) - August 22 at 10:43 AM logoWall Street lower as investors react to Pfizer deal (NASDAQ:MDVN) - August 22 at 10:43 AM logoStocks Pop Higher; Planet Fitness Rises Near High (NASDAQ:MDVN) - August 22 at 10:43 AM logoUnderstanding Medivation’s Premium Valuation (NASDAQ:MDVN) - August 22 at 10:43 AM logo5-Month Timeline: A Look Back At Medivation's Takeover Story (NASDAQ:MDVN) - August 22 at 9:10 AM logoMedivation's stock surges 20% premarket, on track to open at a record high (NASDAQ:MDVN) - August 22 at 8:47 AM
News IconStock Futures Down; Small Caps Lag; Medivation, Syngenta Soar On Merger News (NASDAQ:MDVN) - August 22 at 8:28 AM logoIn possible $14 billion ending, Medivation goes back to early days (NASDAQ:MDVN) - August 22 at 2:57 AM logo3 Reasons Medivation Is the Juiciest Target in Biotech (NASDAQ:MDVN) - August 21 at 12:39 PM
News IconIs Medivation, Inc.(NASDAQ: MDVN), a large market cap stock a smart buy? - The Daily Leicester (NASDAQ:MDVN) - August 20 at 10:14 AM
News IconAnalysts Valuations For Two Stocks: Medivation Inc (NASDAQ:MDVN), Noble Energy, Inc. (NYSE:NBL) - The Voice Registrar (NASDAQ:MDVN) - August 19 at 6:04 PM
News Icon2 Biotech Stocks News And Price Trends: Medivation, Inc. (NASDAQ:MDVN), Intrexon Corporation (NYSE:XON) - The Voice Registrar (NASDAQ:MDVN) - August 19 at 6:04 PM logoMedivation Inc (MDVN): Excellent Opportunity to Get Best Price for its Worth (NASDAQ:MDVN) - August 19 at 9:11 AM logoMedivation Inc (NASDAQ:MDVN): Excellent Opportunity to Get Best Price for its Worth - TCC (NASDAQ:MDVN) - August 18 at 6:15 PM logoMEDIVATION, INC. Financials (NASDAQ:MDVN) - August 18 at 6:15 PM
News IconHow Much Medivation Can Really Fetch in a Buyout (NASDAQ:MDVN) - August 18 at 1:13 PM logoMedivation Inc (MDVN) Takeover Saga: Merck Joins the Fray - Bidness ETC (NASDAQ:MDVN) - August 18 at 9:13 AM logoExclusive - Merck enters race for cancer drugmaker Medivation: sources (NASDAQ:MDVN) - August 17 at 6:20 PM logoMedivation faces buyers’ scrum - report (NASDAQ:MDVN) - August 17 at 6:20 PM logoMedivation shares pop after report that at least five companies interested in deal (NASDAQ:MDVN) - August 17 at 6:20 PM logoEXCLUSIVE-Merck enters race for cancer drugmaker Medivation -sources (NASDAQ:MDVN) - August 17 at 2:44 PM logoMedivation Inc (NASDAQ:MDVN): German Drug Company Plans To Make A Bid Ahead Of Deadline - TCC (NASDAQ:MDVN) - August 12 at 6:13 PM logoETF’s with exposure to Medivation, Inc. : August 12, 2016 (NASDAQ:MDVN) - August 12 at 6:13 PM logoBiotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat (NASDAQ:MDVN) - August 11 at 6:29 PM logoCanaccord Shines Light on Medivation Inc’s (MDVN) 2Q:16 Results (NASDAQ:MDVN) - August 11 at 9:18 AM
News IconMedivation Inc (MDVN) Releases Earnings Results, Beats Expectations By $0.03 EPS (NASDAQ:MDVN) - August 11 at 9:18 AM logoMedivation Inc.: Medivation Reports Second Quarter 2016 Financial Results (NASDAQ:MDVN) - August 10 at 9:07 AM logoCompany Update (NASDAQ:MDVN): Medivation Inc Reports Second Quarter 2016 Financial Results (NASDAQ:MDVN) - August 10 at 9:07 AM logoEdited Transcript of MDVN earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:MDVN) - August 10 at 9:06 AM logoAnalysts' Actions -- Coach, SunPower, Wayfair, Yelp and More (NASDAQ:MDVN) - August 10 at 9:06 AM


Medivation (NASDAQ:MDVN) Chart for Tuesday, August, 23, 2016

Last Updated on 8/23/2016 by Staff